Navigation Links
Labopharm Reports Results for Third Quarter Fiscal 2009
Date:11/6/2009

product for the United Kingdom from its licensing and distribution partner.

Research and development expenses, before research and development tax credits, for the third quarter of fiscal 2009 were $3.5 million compared with $7.3 million for the third quarter of fiscal 2008. The decrease was primarily the result of lower clinical trial costs in the third quarter of fiscal 2009. Research and development tax credits for the third quarter of fiscal 2009 declined to $0.3 million from $1.0 million for the third quarter of fiscal 2008, the result of a deferral in the utilization of non-refundable Canadian federal tax credits due to a change in tax planning.

Selling, general and administrative expenses for the third quarter of fiscal 2009 were $8.0 million compared with $5.0 million for the third quarter of fiscal 2008. The increase is primarily the result of the accrual of $2.7 million for the Company's share of litigation costs incurred by Purdue to enforce certain of Purdue's U.S. patents related to Labopharm's once-daily tramadol product.

Net loss for the third quarter of fiscal 2009 was $6.9 million, or $0.12 per share, compared with $6.0 million, or $0.11 per share, for the third quarter of fiscal 2008.

Cash, cash equivalents and marketable securities at September 30, 2009 were $23.8 million compared with $27.9 million at June 30, 2009. During the third quarter, the Company drew down in its entirety the $2.6 million revolving credit facility with National Bank of Canada, which is collateralized by the Long-Term Notes that the Company received in exchange for the Montreal Proposal ABCP. The Company's cash position at September 30, 2009 does not include the 3.5 million Euros (CAD$5.4 million) up-front payment that Labopharm received under its distribution and supply agreement with Grunenthal GmbH, which was completed subsequent to quarter end.

Nine-Month Period Ended September 30, 2009


'/>"/>
SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Labopharm to present data on its novel trazodone formulation at three upcoming international medical meetings
2. Labopharms response for novel trazodone formulation accepted by FDA as complete - Designated as Class 2 resubmission
3. Labopharm submits response to FDA for novel antidepressant
4. Labopharm Reports Results for Second Quarter Fiscal 2009
5. Labopharm to present at Canaccord Adams 29th Annual Global Growth Conference
6. Labopharm to host conference call Friday, August 7, 2009 at 8:30 a.m. (ET)
7. Labopharm receives complete response letter from the U.S. FDA for novel antidepressant
8. Labopharm amends debt facility agreement with Hercules
9. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
10. Labopharm Reports Results for First Quarter Fiscal 2009
11. Labopharm announces details for first quarter results conference call and annual meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... Indosoft Inc , developers of Q-Suite, a ... to announce the development of Q-Suite 5.9. Building off ... Q-Suite, this new version will include enhancements to existing ... to the leading edge call center software. General availability ... features to enhance security and protection. Administrators will be ...
(Date:2/28/2015)... Carlsbad, CA (PRWEB) February 28, 2015 ... developed a promising new gene therapy procedure for the ... progressive blindness in patients. Authored by Dr. ... Oxford and published in the Lancet Medical Journal on ... suffering from choroideremia, a rare genetic disorder that mostly ...
(Date:2/28/2015)... For those people who are unable to attend ... Research Foundation (Meso Foundation) will broadcast its Symposium ... 9:30 AM. , The live broadcast is free of ... accessed through any browser on a computer or smartphone/device ... a unique event that covers important treatment information and ...
(Date:2/28/2015)... The Mesothelioma Applied Research Foundation ... International Symposium on Malignant Mesothelioma on Monday, March 2. ... Regency Bethesda in Bethesda, Maryland. The following award recipients ... to the mission to cure mesothelioma. , The Klaus ... to Miriam Ratner. Miriam runs the Meso Foundation’s monthly ...
(Date:2/28/2015)... Pioneer Millworks reclaimed USA wood will be on ... Show, an annual, premier sustainable building event in Tokyo, ... manufacturers of the latest building products, services and technology. ... manufactured by Pioneer Millworks from their Oregon and New ... hotels, retailers, and corporate offices. Nichibi Global , ...
Breaking Medicine News(10 mins):Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2
... (Pink Sheets: HRAL)-,HearAtLast Holdings, Inc. is proud to ... (NYSE: WMT ) to open its 17th hearing-aid,clinic ... at 450,Stevenson Road South, Oshawa, Ontario. The clinic officially ... to the HearAtLast chain. The,Company currently owns and operates ...
... Inc. (Nasdaq: MLNM ) today announced ... Global Pharmaceutical, Biotechnology and Medical,Device Conference will ... by visiting the,Investors section of the Company,s ... http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO ), During the presentation, ...
... Confirms Part D Seniors Also Enjoy Broad Choice of,Prescription ... Association (PCMA) issued the following statement on new budget,figures ... is lower over the,next ten years than was estimated ... without sacrificing beneficiaries,choice of prescription drugs. New budget documents ...
... 31 In hopes of gaining a better,grasp on ... more on sales training tools and techniques to,provide their ... first year of training and preparation is critical for ... of approximately $10,500 in,the first year of employment, more ...
... to Slash Most Vulnerable Seniors, Nursing Home Care to ... on a New,York Times article today reporting the Bush ... in his FY 2009 budget to,be unveiled Monday, the ... up to fight the cut, as it did last ...
... 2008 All candidates running for office in 2008 should ... for the United States that is second to none the ... report on The State of the Nations Health Care. In ... gain candidate commitments to support a series of recommendations. , ...
Cached Medicine News:Health News:HearAtLast Expands Chain to 17 Locations, Opening New Clinic in Oshawa, Ontario Wal-Mart Supercenter # 1056 2Health News:HearAtLast Expands Chain to 17 Locations, Opening New Clinic in Oshawa, Ontario Wal-Mart Supercenter # 1056 3Health News:HearAtLast Expands Chain to 17 Locations, Opening New Clinic in Oshawa, Ontario Wal-Mart Supercenter # 1056 4Health News:2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference to Webcast Millennium Presentation 2Health News:Vital Training Tools Elevate New Pharmaceutical Sales Reps into Top Performers During Critical First Year 2Health News:Coalition to Protect Senior Care Gearing Up to Fight Bush Administration Medicare Cuts 2Health News:Achieving a US health care system 'second to none' 2Health News:Achieving a US health care system 'second to none' 3Health News:Achieving a US health care system 'second to none' 4
(Date:2/27/2015)... , Israele, February 27, 2015 ... nel suo sviluppo dell,innovativo sistema di monitoraggio dell,infarto ... primo trial sull,uomo-     ... nello sviluppo di nuovo sistema per il monitoraggio ... (CHF), ha annunciato oggi di aver concluso una ...
(Date:2/27/2015)... Calif., Feb. 27, 2015 Isis Pharmaceuticals, Inc. ... outperformed both its pro forma net operating loss (NOL) ... a strong financial position.  Isis, significantly improved financial results ... $230 million in payments the Company received from its ... 2014 was a nearly 60% improvement over its 2013 ...
(Date:2/27/2015)... -- An aggressive campaign to reduce the unnecessary use ... with a dangerous drug-resistant bacteria at The Valley Hospital ... C.diff, is a bacterium that can cause symptoms ranging ... recent article in the New England Journal of Medicine ... the United States " asserts that "C. difficile ...
Breaking Medicine Technology:Vectorious Medical Technologies completa una raccolta di 5 milioni di dollari 2Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 3
Disposable or reusable AEM cord for use with 5mm AEM Laparoscopic Instruments ....
... offers protection in three ... values with lightweight comfort ... quality. Lenses provide .75 ... are anti-reflection coated and ...
... frontal protection, our conventional aprons ... by sturdy 2 webbed straps ... snap hook fasteners. The straps ... fit the apron. Our conventional ...
... always been a popular choice. Thats because ... Our new design is even more comfortable! ... velcro closures to adjust the fit more ... fully protect your neck. All .5mm lead ...
Medicine Products: